Targeted Therapies for Cancer

SeattleGenetics®

2017 PHARMACY FELLOWSHIP PROGRAM
At Seattle Genetics, we are focused on developing innovative antibody-based therapies that improve outcomes for people with cancer. We are dedicated to addressing unmet medical needs, and strive to achieve that goal through excellence in research and development.
Antibody-drug conjugates (ADCs) are designed to deliver cell-killing agents directly to the target cell, sparing non-targeted cells and thereby reducing the toxic effects of traditional chemotherapy while enhancing antitumor activity.

We have built a strong corporate culture around the values of integrity, scientific excellence, teamwork, innovation, mutual respect, an inspiring work environment and a passion for helping patients. Seattle Genetics embodies an entrepreneurial spirit that advances breakthrough therapies, which is why we are the leader today in antibody-drug conjugate technology.
Industry-Leading Antibody-Drug Conjugates

Our ADC technology empowers monoclonal antibodies to fight cancer. We have developed proprietary technology combining potent synthetic cell-killing (cytotoxic) agents and stable linkers that attach the cytotoxic agent to an antibody. The antibody is targeted against a specific tumor-associated receptor on cancer cell surfaces. Our linker systems release the cytotoxic agent once inside the targeted cells. This approach is intended to spare non-targeted cells and reduce the toxic effects of traditional chemotherapy while enhancing antitumor activity.

Targeted Delivery of a Potent Cytotoxic Agent

The key components of our ADC technology are the stable linkers and synthetic cytotoxic agents. Our linkers have been shown in preclinical models to be up to 10 times more stable in blood than conventional means of attaching drugs to antibodies. The lead group of cytotoxic agents that we have developed is a class of microtubule-disrupting agents called auristatins. In preclinical models, these auristatins are 100- to 1,000-fold more potent than traditional chemotherapy drugs. We are also evaluating a second proprietary ADC technology using a highly potent cytotoxic agent called a pyrrolobenzodiazepine (PBD) dimer that kills cells by a different mechanism than auristatins. The agent is stably linked to an engineered antibody with our site-specific conjugation technology, resulting in uniform drug-loading of two PBD dimers per antibody. We call this engineered antibody an EC-mAb.

We are conducting significant research activities to continue advancing our ADC technology. These efforts are focused on developing new classes of stable linkers and potent cell-killing agents, identifying new cancer targets, and advancing our antibody engineering initiatives. We are committed to remaining the leader in ADC development.

Expanding Our Opportunities Through Collaboration

Collaborating with other leading biotechnology and pharmaceutical companies is a strategy that advances the development and commercialization of product candidates and supplements our internal pipeline. Technology licensing agreements for our ADC technology generate financial benefit, and extend the reach of our technology into programs being developed by our collaborators—in some cases, providing us with future pipeline opportunities through co-development or opt-in rights to new ADC product candidates.

Advancing Antibody-Drug Conjugates for Cancer

“Seattle Genetics was founded on our belief that antibodies offer a powerful approach to targeting disease and improving patient outcomes. By harnessing our ADC technology, we are developing empowered antibodies designed to address significant unmet medical needs and drive new treatment paradigms.”

Clay B. Siegall, Ph.D.  President and Chief Executive Officer, Seattle Genetics
Our ADC technology empowers more than 20 of the ADCs in clinical development across the industry, including both proprietary and collaborator programs. Our goal is to employ the power of our ADC technology to improve efficacy and decrease toxicity in a target-specific manner across multiple tumor types.

Monoclonal antibodies targeted to a specific tumor-associated receptor on target cells are attached to a cytotoxic agent with a stable proprietary linker. Below, an ADC binds to a receptor and is internalized into the cell where the cytotoxic agent is released, resulting in cell death.
Across corporate and investigator studies, ADCETRIS® (brentuximab vedotin) is in more than 70 clinical trials. These studies are designed to broadly evaluate its potential in earlier lines of its approved indications as well as many additional types of CD30-expressing lymphomas.

ADCETRIS Clinical Development
ADCETRIS® (brentuximab vedotin) is commercially available in 65 countries, including the U.S., Canada, Japan and members of the European Union. It was granted accelerated approval in the U.S. in 2011 for relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL), a type of mature T-cell lymphoma (MTCL). In August 2015, ADCETRIS was fully approved for relapsed classical HL and approved for a third indication in the U.S. as classical HL post-auto-HSCT consolidation. We believe these approvals are just the beginning for this product. In collaboration with our partner, Takeda Pharmaceutical Company Limited, we are conducting a broad clinical development program to evaluate ADCETRIS in earlier lines of HL and MTCL therapy as well as in an array of other CD30-expressing malignancies.

Continuing to Innovate
Building on the momentum of ADCETRIS, we are aggressively advancing a robust pipeline of antibody-based therapies. This includes eight ADCs and one immuno-oncology agent that are in clinical trials targeting a number of hematologic malignancies and solid tumor types. We continue to innovate with new technologies, engineered antibodies, novel linkers and potent cytotoxic agents. Multiple collaborator programs provide further validation and understanding of the potential of our ADC technology and represent additional sources of future revenue. For more information visit www.seattlegenetics.com.

Our Product Pipeline
A Robust Pipeline

Realizing the ADCETRIS opportunity

We have a broad ADCETRIS® (brentuximab vedotin) clinical development program evaluating its potential to become the foundation of therapy for CD30-expressing lymphomas.

<table>
<thead>
<tr>
<th>THERAPEUTIC AREA</th>
<th>PRE-CLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALCANZA: Relapsed CD30-expressing cutaneous T-cell lymphoma (top line data reported)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECHELON-1: Frontline HL (chemotherapy +/- brentuximab vedotin) (enrollment complete)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECHELON-2: Frontline CD30-expressing mature T-cell lymphoma (chemotherapy +/- brentuximab vedotin) (enrollment complete)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frontline diffuse large B-cell lymphoma (DLBCL) (rituximab + chemotherapy +/- brentuximab vedotin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapsed CD30-expressing DLBCL (rituximab + bendamustine +/- brentuximab vedotin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frontline HL, age 60+ (+/- chemotherapy or nivolumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Second-line HL (+ nivolumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapsed non-Hodgkin lymphoma (NHL) (+ nivolumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**A diversified pipeline of clinical-stage programs**

Our pipeline of antibody-based therapies is designed to address the unmet medical needs of people with cancer. We believe our technology will empower a new generation of cancer therapies.

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>THERAPEUTIC AREA</th>
<th>PRE-CLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>SGN-CD33A (vadastuximab talirine)</td>
<td>CASCADE: Frontline older acute myeloid leukemia (AML) (+ HMA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frontline myelodysplastic syndrome (MDS) (+ HMA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relapsed AML pre/post allo-transplant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frontline AML (+ chemotherapy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AML (monotherapy and + HMA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGN-CD19A (denintuzumab mafodotin)</td>
<td>Relapsed DLBCL (rituximab + chemotherapy +/- SGN-CD19A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frontline DLBCL (+ chemotherapy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGN-LIV1A</td>
<td>Metastatic breast cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASG-22ME* (enfortumab vedotin)</td>
<td>Metastatic urothelial cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASG-15ME*</td>
<td>Metastatic urothelial cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEA-CD40</td>
<td>Metastatic or unresectable solid tumors; hematologic malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGN-CD19B</td>
<td>Relapsed NHL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGN-CD123A</td>
<td>AML</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGN-CD352A</td>
<td>Multiple myeloma (planned)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGN-2FF</td>
<td>Solid tumors (planned)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGN-CD48A</td>
<td>Multiple myeloma (planned)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Program being developed in collaboration with Astellas
These are investigational uses and efficacy/safety have not been established.
Seattle Genetics is an emerging biotechnology company looking for Pharmacy Fellows to join its growing team in the Pacific Northwest. The objective of the Seattle Genetics pharmacy fellowship program is to provide pharmacists with industry and business experience to complement their clinical training. The 1-year training program is meant to serve as a strong foundation for a career in biotechnology.

1 Year Fellowship: **Oncology Marketing**

The Oncology Marketing fellowship at Seattle Genetics offers a unique opportunity to pair one’s Pharm.D. training with hands on commercial experience in biotechnology. The fellow will assist and lead a variety of projects within the Marketing group while interacting with personnel from Sales, Market Planning, Managed Markets as well as key cross-functional groups including Medical Affairs, Regulatory Affairs, and Clinical Development. The fellow will also have opportunities to participate in strategic marketing initiatives, including the development of brand and tactical plans.

**SPECIFIC RESPONSIBILITIES WILL INCLUDE:**

- Assist and eventually manage the development and execution of select branded and unbranded promotional materials
- Support key logistical activities, notably those related to the promotional review committee and promotional material fulfillment
- Review and summarize key insights from emerging clinical data in the oncology space
- Develop and deliver presentations as needed to the marketing team and other internal groups
- Support the management of advertising agencies and other commercial vendors
- Work collaboratively, effectively and efficiently with all internal and external partners and stakeholders
- Travel may include, but is not limited to, attendance at key sales and marketing meetings, as well as attendance at annual ASCO and ASH meetings

“It is an exciting time within the Commercial organization at Seattle Genetics as we lead education efforts for the approved indications of ADCETRIS in the US as well as support our growing pipeline globally.” — Matt Skelton
1 Year Fellowship: Medical Affairs

The Medical Affairs Fellowship represents an excellent opportunity for a Pharm.D. to gain pharmaceutical industry experience and expand their clinical knowledge through active participation on the Medical Affairs team. The fellow will have the opportunity to obtain an understanding of the role of Medical Affairs in the biopharmaceutical industry; develop clinical data analysis, interpretation, and communication skills; gain the ability to recognize unmet patient needs and render clinical insights; develop industry-appropriate professional skills. The fellow will have opportunities to gain experience with Medical Information, Medical Communications, Clinical Value and Outcomes, Scientific Alliances, Medical Education, Medical Director and Medical Science Liaison teams. The fellow will also interact with key cross-functional groups including Commercial, Regulatory, and Clinical Development.

SPECIFIC RESPONSIBILITIES WILL INCLUDE:

- Training and mentoring in Medical Affairs-related skill areas and exposure to related aspects in the pharmaceutical industry
- Participate in Medical Affairs-related congress planning and activities
- Create and execute a longitudinal project(s)
- Give regular presentations of Medical Affairs-related topics
- Support Medical Affairs functional activities, integrating learnings and clinical insights into projects and initiatives
- Work collaboratively with internal and external partners and stakeholders
- Travel may include, but is not limited to, the annual ASCO/ASH meetings and ASHP Midyear

“The Medical Affairs fellowship represents an excellent opportunity for a fellow to gain meaningful experience in Medical Affairs while working closely with internal and external lymphoma experts to further clinical research at Seattle Genetics.” — Nancy Whiting, Pharm.D., BCOP

Vice President, Medical Affairs
1 Year Fellowship: **Drug Safety**

The Drug Safety Fellowship at Seattle Genetics, Inc. offers an opportunity to apply one’s clinical knowledge and analytical skills while gaining a thorough understanding of pharmacovigilance across the product life cycle. Fellows will work closely with the Safety Evaluation and Risk Management (SERM) Lead in single case evaluation, aggregate data analysis, signal detection and evaluations. Additionally, the fellow will have opportunity to gain experience through strategic interactions with key cross-functional team members, such as Non-Clinical Development, Drug Safety Operations, Clinical Development, Clinical Information Systems, Regulatory Affairs, and Medical Affairs.

**SPECIFIC RESPONSIBILITIES MAY INCLUDE:**

- Contribute to Pharmacovigilance and Risk Management planning for designated products
- Track and evaluate potential safety issues
- Perform Project Management activities for multiple studies in a program
- Support the SERM lead in the development and/or execution of RMP or REMS risk mitigation activities
- Conduct/support signal detection and evaluation according to SOPs and guidelines
- Prepare Safety Evaluation Reports as necessary for safety signals or other issues (product quality)
- Provide safety content review of clinical protocols, study reports, informed consent forms, and Investigator Brochures for designated products
- Support the SERM Lead in responding to safety requests for assigned product(s) from Regulatory Authorities, Affiliates and other internal functions
- Attend weekly SERM meeting to relay safety concerns raised in Study Team/Clinical Sub Team Meetings

Sundos Hamza
Senior VP Risk Management and Pharmacovigilance

“The Drug Safety fellowship is a fantastic opportunity for a fellow to jumpstart their career in pharmacovigilance during an exciting time at Seattle Genetics.”

— Sundos Hamza
Seattle Genetics Headquarters is located 25 minutes driving from Downtown Seattle.

Seattle Genetics is committed to professional development

Fellows will have some of the following opportunities for concurrent professional development during the fellowship:

- Seattle Genetics Executive 1:1 Series
- Publication Opportunities
- Participation in Company Leadership Development Classes
- Virtual business and project management training
- Opportunity to shadow Commercial Sales and Medical Affairs MSL field personnel
- Option for cross-functional rotation
- Opportunity to precept pharmacy students

Employee Benefits

COMPENSATION:
- Competitive base pay: We set high goals for our employees and reward hard work with competitive salaries
- Bonus opportunity: We offer a discretionary bonus based on the successful accomplishment of corporate and individual goals
- Relocation package: We support new employees with the costs and logistics of moving to the Seattle area

HEALTH & WELLNESS:
- We are committed to a comprehensive employee benefit program
- Seattle Genetics contributes a significant portion towards health care premiums for qualified employees, spouses, domestic partners and dependents

SAVINGS OPPORTUNITIES:
- 401(k) and matching contribution
- Flexible spending accounts for health and dependent care

WORK-LIFE BALANCE:
Seattle Genetics recognizes that time away from work is essential to employees’ health and productivity. We demonstrate our dedication and appreciation to our employees by these generous time-off practices.
- Paid vacation
- Paid sick
- Holiday schedule: There are eight fixed holidays, in addition to optional holidays
Fellowships will commence in July of 2017 and run for one calendar year

To Apply:
Candidates may request an interview through the ASHP PPS service.
All candidates must have graduated from an ACPE accredited Pharmacy School prior to fellowship start date.

General Fellowship Program Inquiries:
Zachary Crouch, Pharm.D.
Associate Director, Marketing
Pharmacy Fellowship Director
Seattle Genetics
fellowship@seagen.com

Seattle Genetics Corporate Headquarters:
21823 – 30th Drive S.E.
Bothell, WA 98021